Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer

[1]  J. Robertson,et al.  Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. , 1999, European journal of cancer.

[2]  G. Stancel,et al.  The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription. , 1999, Cancer research.

[3]  G. Stancel,et al.  Progestin regulation of vascular endothelial growth factor in human breast cancer cells. , 1998, Cancer research.

[4]  R. Sutherland,et al.  Antiprogestin inhibition of cell cycle progression in T-47D breast cancer cells is accompanied by induction of the cyclin-dependent kinase inhibitor p21. , 1997, Molecular endocrinology.

[5]  E. Eisenhauer,et al.  Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Hannig,et al.  Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells. , 1996, European journal of cancer.

[7]  J. Foekens,et al.  Pre-clinical and clinical treatment of breast cancer with antiprogestins. , 1994, Human reproduction.

[8]  J. Klijn,et al.  Effects of progestagens and Org OD14 in in vitro and in vivo tumor models , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  A. Howell.  Endocrine therapy of breast cancer VI , 1994 .

[10]  C. Bardin,et al.  Mifepristone (RU 486)--a modulator of progestin and glucocorticoid action. , 1993, The New England journal of medicine.

[11]  J. Foekens,et al.  Clinical breast cancer, new developments in selection and endocrine treatment of patients , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  G. Vollmer,et al.  Down-regulation of tenascin expression by antiprogestins during terminal differentiation of rat mammary tumors. , 1992, Cancer research.

[13]  K. Horwitz,et al.  The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? , 1992, Endocrine reviews.

[14]  W. McGuire,et al.  Progesterone antagonists: Tumor-inhibiting potential and mechanism of action , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[15]  M. F. Etreby,et al.  Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  J. Foekens,et al.  Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  C. Redmond,et al.  Endocrine treatment of breast cancer in women. , 1990, Endocrine reviews.

[18]  J. Foekens,et al.  Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. , 1989, Endocrinology.

[19]  J. Klijn,et al.  Antiprogestins, a new form of endocrine therapy for human breast cancer. , 1989, Cancer research.

[20]  M. E. El Etreby,et al.  Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat. , 1989, European journal of cancer & clinical oncology.

[21]  M. E. El Etreby,et al.  The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death. , 1989, Journal of steroid biochemistry.

[22]  J. Klijn,et al.  Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. , 1987, Cancer treatment reports.

[23]  J. Klijn,et al.  Effects of the progesterone antagonist RU486 on ovarian activity in the rat. , 1987, Endocrinology.

[24]  H. Rochefort,et al.  Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells. , 1987, Cancer research.

[25]  G. Romieu,et al.  The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. , 1986, Bulletin du cancer.

[26]  J. Foekens,et al.  Hormonal manipulation of cancer : peptides, growth factors, and new (anti)steroidal agents , 1987 .

[27]  K. Horwitz,et al.  The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells. , 1985, Endocrinology.

[28]  D. Chalbos,et al.  RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor. , 1985, The Journal of clinical endocrinology and metabolism.

[29]  D. Chalbos,et al.  Dual effects of the progestin R5020 on proteins released by the T47D human breast cancer cells. , 1984, The Journal of biological chemistry.